AMGNAmgenRunning, no new patients
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
3 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 303 (final count)
- Started
- Nov 2, 2021
- Main results expected
- Sep 7, 2029
- Fully finished
- Jun 30, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Safety run-in: Number of Participants who Experience Treatment-emergent Adverse Events (TEAEs)
Measured over: Up to approximately 5 years
Phase 3: Event-free Survival (EFS)
Measured over: Up to approximately 5 years
Phase 3: Overall Survival (OS)
Measured over: Up to approximately 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04994717 · record last updated 2026-06-30 · checked 2026-11-09 15:47 UTC